The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...

Both ibuprofen and naproxen potently inhibit hTAS1R2–TAS1R3 receptors that sense sweetness in a dose-dependent manner. The ...

It is a common belief that low-dose dopamine may be helpful in the prevention and treatment of acute renal failure and is being widely used in these situations. Does dopamine have a beneficial ...

Pluvicto is a radioligand therapeutic agent containing the active moiety, lutetium-177, which binds to PSMA, a transmembrane protein that is expressed in prostate cancer. Once bound, the beta ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...